FDA Requires Vision Loss Warning on GLP-1 Diabetes and Weight-Loss Medications

The U.S. Food and Drug Administration (FDA) is mandating new warnings for GLP-1 receptor agonist medications, such as Ozempic and Wegovy, regarding a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). This rare eye condition can cause sudden, permanent vision loss in one eye. The FDA's decision, based on clinical trial and real-world data, aims to inform patients and prescribers about this serious potential side effect for widely used diabetes and weight-loss drugs.